According to the GMI Research latest report, the global insulin delivery devices market is estimated to be at USD 9,367.9 million in 2017 and is anticipated to reach USD 14,198.3million by 2025, growing at a CAGR of 5.4% during 2018–2025.

To have an edge over the competition by knowing the market dynamics and current trends of “Insulin Delivery Devices Market”, request for Sample Report here

Figure 1: Global Insulin Delivery Devices Market Revenue, 2018–2025 (USD Million)

Source: GMI Research

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

The global insulin delivery devices market is gaining traction over the coming years. The drastic rise in the number of diabetic patients has been the primary driving factors responsible for the strong demand of the market. According to the Centers for Disease Control and Prevention (CDC), around 29.1 million people in the U.S. have diabetes and approximately 4.6 – 9.2% of pregnant women are affected by gestational diabetes.

The manufacturers around the world are emphasizing on bringing technological advancement in the insulin delivery systems to gain a competitive edge over the other leading players. For example, Novo Nordisk, a multinational pharmaceutical company, launched its first insulin pen, NovoPen Echo in the U.S. market. With the accelerating penetration of the internet, the consumers have become more aware regarding the different delivery devices available in the market. The insulin pen provides enhanced efficiency, has a longer lifespan, and offers better dosing accuracy, particularly at low doses.

The drastic change in the lifestyle pattern of the consumers is the major reason for accelerated number diabetes cases. Patients now prefer syringes and insulin pens rather than the traditional insulin devices as they are highly cost-effective, easily available, and offers numerous refining policies for compensation. The continued rising demand for advanced insulin devices will have a long-term positive effect on the market. Despite of the current COVID-19 pandemic, the global market for insulin delivery devices remains stable. As the governments of different regions have already announced total lockdown and temporary shutdown of industries, the diabetes patients are largely adopting the method of self-monitoring and insulin delivery at their home by using advanced insulin devices, such as insulin pens and syringes.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here

Figure 2: Global Insulin Delivery Devices Market Revenue, by Region, 2017

Source: GMI Research

For detailed scope of the “Insulin Delivery Devices Market” report request a Sample Copy of the report

Insulin is considered essential for patients who have type 1 diabetes and type 2 diabetes. The improvement in the insulin delivery devices has eased the process of injecting insulin into the patient’s body. The North-America region is largely contributing to the expanding demand of the market. The rapid technological advancement in the devices, followed by the large presence of leading players in this region, are the significant factors that will positively impact the potential growth of the market. The favorable policies and programs launched by the government are further supporting the market.

Various notable players operating in global insulin delivery devices market include Abbott Laboratories, Ypsomad Holding AG, F. Hoffmann-La Roche Ltd, Terumo Corporation, Insulet Corporation, Medtronic, Animas Corporation, Becton, Dickinson and Company, Dexcom, Inc., Sanofi, among others.

The global insulin delivery devices market has been segmented on the basis of product type, end user and key regions. Based on product type, the market comprises of Insulin Pens, Insulin Pumps, Pen Needles, Insulin Syringes and Others. The end user segment includes, Patients/Homecare and Hospitals & Clinics.

Key questions answered in this research report:

• • At what pace is global Insulin Delivery Devices market growing? What will be the growth trend in the future?
  • What are the key drivers and restraints in Insulin Delivery Devices market? What will be the impact of drivers and restraints in the future?
  • What are the regional revenues and forecast breakdowns? Which are the major regional revenue pockets for growth in the global Insulin Delivery Devices market?
  • Which Product Type generated maximum revenues in 2017 and identify the most promising Product Type during the forecast period?
  • What are the various End User areas of global Insulin Delivery Devices market and how they are poised to grow?
  • What companies are the major participants in this market and their business strategies, how does the competitive landscape look like?

 

Report Coverage	Details
Market Base Year	2017
Market Forecast Period	2018-2025
Market Revenues Currency	USD Million
Base Year & Forecast Units	Revenues (USD Million)
Market Segment	By Product Type, By End User, By Region
Regional Coverage	Asia Pacific, Europe, North America, and RoW
Companies Profiled	Abbott Laboratories, Ypsomad Holding AG, F. Hoffmann-La Roche Ltd, Terumo Corporation, Insulet Corporation, Medtronic, Animas Corporation, Becton, Dickinson and Company, Dexcom, Inc., Sanofi., among others; a total of 11 companies covered.
25% Free Customization Available	We will customize this report up to 25% as a free customization to address our client’s specific requirements

 

Market Segmentation

Global Insulin Delivery Devices Market by Product Type

• • Insulin Pens
    • Reusable Insulin Pens
    • Disposable Insulin Pens
  • Insulin Pumps
    • External/Tethered Pumps
    • Patch Pumps
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles
  • Insulin Syringes
  • Others

Global Insulin Delivery Devices Market by End User

• • Patients/Homecare
  • Hospitals & Clinics

Global Insulin Delivery Devices Market by Region

• • North America Insulin Delivery Devices Market
    (Option 1: As a part of the free 25% customization)
    • North America Market by Product Type
    • North America Market by End User
    • United States of America (US) Market All-Up
    • Canada Market All-Up
  • Europe Insulin Delivery Devices Market
    (Option 2: As a part of the free 25% customization)
    • Europe Market by Product Type
    • Europe Market by End User
    • United Kingdom (UK) Market All-Up
    • Germany All-Up Market All-Up
    • France Market All-Up
    • Spain Market All-Up
    • Rest of Europe Market All-Up
  • Asia-Pacific Insulin Delivery Devices Market
    (Option 3: As a part of the free 25% customization)
    • Asia-Pacific Market by Product Type
    • Asia-Pacific Market by End User
    • China Market All-Up
    • India Market All-Up
    • Japan Market All-Up
    • Rest of APAC Market All-Up
  • RoW Insulin Delivery Devices Market
    (Option 4: As a part of the free 25% customization)
    • RoW Market by Product Type
    • RoW Market by End User
    • Brazil Market All-Up
    • South Africa Market All-Up
    • Saudi Arabia Market All-Up
    • UAE Market All-Up
    • Rest of world (remaining countries of the LAMEA region) Market All-Up

Major Players Operating the Insulin Delivery Devices (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • Abbott Laboratories
  • Ypsomad Holding AG
  • F. Hoffmann-La Roche Ltd
  • Terumo Corporation
  • Insulet Corporation
  • Medtronic
  • Animas Corporation
  • Becton
  • Dickinson and Company
  • Dexcom, Inc.
  • Sanofi